61%
of retail accounts lose money when trading CFDs with this provider.
Investments involve risks and are not suitable for all investors. CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage.
61%
of retail investor accounts lose money when trading CFDs with this provider.
You should consider whether you understand how CFDs work, and whether you can afford to take the high risk of losing your money.
61%
of retail accounts lose money when trading CFDs with this provider.
Investments involve risks and are not suitable for all investors. CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage.
61%
of retail investor accounts lose money when trading CFDs with this provider.
You should consider whether you understand how CFDs work, and whether you can afford to take the high risk of losing your money.
English (International)
Gilead Sciences Inc.
Closed
Sector Healthcare
91.76 0.25
Overview
Share price change
24h
Min
91.76
Max
92.31
Income | -361M 1.3B |
|---|---|
Sales | 540M 7.5B |
P/E Sector Avg | 102.24 59.526 |
EPS | 2.02 |
Dividend yield | 3.674 |
Profit margin | 16.618 |
EBITDA | 780M 3.8B |
Recommendations | Buy |
|---|---|
12 Months Forecast | +8.11 upside |
Dividend yield Sector Avg | 3.67% 2.33% |
|---|---|
Next Earnings | 4 Feb 2025 |
Next Dividend date | 27 Mar 2025 |
Next Ex Dividend date | 13 Mar 2025 |
Market Cap | 436M 115B |
|---|---|
Previous open | 91.51 |
Previous close | 91.76 |
News Sentiment
By Acuity
8%
92%
5 / 392 Healthcare
Technical Score
By Trading Central
Confidence
Bullish Evidence
Gilead Sciences Inc. Chart
Past performance is not a reliable indicator of future results.
Related News
Peer Comparison
Price change
Gilead Sciences Inc. Forecast
Price Target
By TipRanks
8.11% upside
12 Months Forecast
Average 99.29 USD 8.11%
High 125 USD
Low 73 USD
Based on 26 Wall Street analysts offering 12 month price targets forGilead Sciences Inc. - Dist in the last 3 months.
Sentiment
By Acuity
5 / 392 Healthcare
News Sentiment
Very Strong Bullish Evidence
Volatility
Below average
News Volume (RCV)
Below average
Financials
Selling and administration expenses
Operating expenses
Pre-tax profit
Sales
Cost of sales
Gross profit on sales
Interest expense on debt
EBITDA
Operating profit
$
About Gilead Sciences Inc.
Gilead Sciences, Inc. is a biopharmaceutical company that is focused on advancing medicines to prevent and treat diseases, including human immunodeficiency virus (HIV), viral hepatitis and cancer. The Company's portfolio of products and pipeline of investigational drugs includes treatments for HIV/acquired immune deficiency syndrome (AIDS), COVID-19, liver diseases, hematology/oncology/cell therapy and other. Its products for HIV/AIDS patients include Biktarvy, Descovy, Odefsey, Genvoya, Stribild, Complera/Eviplera, Truvada and Atripla. It offers Veklury to patients with COVID-19. The Company's products for patients with liver diseases include Vemlidy, Epclusa, Harvoni, Viread and Vosevi. Its products under hematology/oncology/cell therapy include Yescarta, Tecartus, Trodelvy and Zydelig. Other products include Letairis, Ranexa and AmBisome. Its products for various inflammation/respiratory diseases include Cayston and Tamiflu. The Company operates in more than 335 countries worldwide.
